In Depth 20 Dec 2022 Ebvallo approval ushers in off-the-shelf T-cell immunotherapies Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU approval of Atara Biotherapeutics’ Ebvallo marks the first immunotherapy based on T cells sourced from healthy donors. Since the approvals of Kymriah and Yescarta in 2017, CAR-T immunotherapies have changed the way we treat rare forms of blood cancer. In […] December 20, 2022 - 6 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Watch: Sernova’s Cell Pouch System tackles diabetes Sernova Corp. is a Canadian-based clinical-stage biotechnology company that is developing its Cell Pouch System. This is a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a […] December 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Watch: Interview with IRBM’s Heidi Kingdon Jones The IRBM Group is an innovative research and discovery CRO (contract research organization) working across all aspects of drug discovery and early development. Headquartered in Italy, the company fosters collaborations with organizations from the pharma, biotech, non-profit and academic sectors to accelerate the development of vaccines and medicines. About 250 scientists work at the company’s […] December 20, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Watch: Valo Therapeutics at Bio-Europe Valo Therapeutics Oy is a Finnish immunotherapy company developing antigen-coated oncolytic viruses and vaccine vectors as innovative immunotherapy approaches against cancer and infectious disease. The Valo Therapeutics lead platform, PeptiCRAd (Peptide-coated Conditionally Replicating Adenovirus), was developed at the laboratory of Vincenzo Cerullo at the University of Helsinki in Finland. It turns oncolytic adenoviruses into targeted […] December 20, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Watch: SwedenBIO leading the way SwedenBIO is the national non-profit association for the life science industry in Sweden, with more than 300 members. December 20, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Watch: Sigrid CEO talks about lifestyle diseases Sigrid Therapeutics AB was founded in 2014 by Tore Bengtsson and Sana Alajmovic, with the vision of transforming the way modern day chronic lifestyle diseases are treated and prevented. The company’s research dates back to 2008 when Bengtsson and his research group at the Department of Molecular Biosciences at Stockholm University in Sweden made discoveries […] December 20, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Watch: IRLAB CEO Richard Godfrey IRLAB discovers and develops novel treatments of Parkinson’s disease and other CNS disorders. The company’s most advanced drug candidates, mesdopetam (IRL790) and pirepemat (IRL752), are in phase IIb and are designed to treat some of the most difficult symptoms related to Parkinson’s disease. In 2021, Ipsen, a specialty pharma company, acquired exclusive global rights to […] December 20, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Watch: Mendus interview Mendus AB is a Swedish company dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. The company leverages its expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy […] December 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Ori Biotech and Inceptor Bio partner on solid tumor cell therapy Cell and gene therapy (CGT) company Ori Biotech, and cell therapy firm Inceptor Bio have announced a new partnership. The deal will utilize Ori Biotech’s manufacturing platform technology to support initial process development through scale-up for manufacturing of Inceptor’s novel CAR-M, CAR-T and CAR-NK programs. Inceptor Bio is the third partner to join Ori’s LightSpeed […] December 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Verona Pharma drug meets COPD phase 3 trial endpoints Verona Pharma plc has announced positive results of its phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD). The ENHANCE-1 trial successfully met its primary and key secondary endpoints demonstrating significant improvements in lung function, symptoms and quality of life measures. In addition, ensifentrine substantially reduced the […] December 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 Ribbon Biolabs milestone to lead to 2023 market entry DNA synthesis company Ribbon Biolabs has announced the successful implementation of its InfiniSynth platform for the automated assembly of sequence-agnostic and long DNA. The company achieved the milestone in collaboration with HighRes Biosolutions, a laboratory automation technology company. The InfiniSynth platform enables Ribbon Biolabs to enter the market in 2023 with a highly differentiated approach […] December 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Dec 2022 iOnctura raises €17.5M for pancreatic cancer therapy iOnctura BV, a clinical-stage biotech developing novel cancer therapies, has been granted €17.5 million ($18.6 million) funding from the European Investment Council’s (EIC) accelerator program to develop IOA-289 for pancreatic cancer. The EIC’s funding consists of a grant of €2.5 million ($2.7 million), and €15 million ($16 million) of equity investment. Earlier this month, iOnctura […] December 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email